Form 4: Director Nancy Lurker Acquires Collegium Pharma Stock

Director Nancy Lurker of Collegium Pharmaceutical, Inc. acquired 8,741 shares of common stock through the grant of restricted stock units.

Summary

• Director Nancy Lurker was granted 8,741 restricted stock units (RSUs) on May 14, 2026.
• Each RSU represents a contingent right to receive one share of Collegium Pharmaceutical, Inc. common stock.
• The RSUs are set to vest on May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, provided Ms. Lurker continues her service.
• Settlement of the RSUs will occur on the vesting date or, at the director's election, earlier upon the end of her board service, death, disability, or a change in control.
• Following this transaction, Ms. Lurker beneficially owns 26,758 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard equity grant to a director rather than significant financial performance or strategic shifts.

Positives

• Director compensation through equity awards like RSUs aligns management interests with shareholders.
• The grant of RSUs indicates continued confidence in the company's future prospects by a key insider.
• Ms. Lurker's continued service is a condition for vesting, suggesting commitment to the company.

Negatives

• The filing does not provide specific financial performance data, making it difficult to assess the immediate impact on the company's financial health.
• The value of the RSUs is contingent on future vesting and stock price performance.

Risks

• The vesting of RSUs is subject to continued service, meaning a departure from the board would impact the realization of these awards.
• The ultimate value of the RSUs is tied to the future stock price of Collegium Pharmaceutical, Inc., which is subject to market volatility.
• A change in control of the Issuer could trigger earlier settlement of the RSUs, the terms of which are not detailed in this filing.

Future Outlook

The RSUs granted to Director Nancy Lurker are subject to vesting on May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, contingent upon her continued service. Settlement will occur on the vesting date or potentially earlier under specific conditions such as director's departure, death, disability, or a change in control.

Industry Context

StockSavvy.ai notes that equity grants to directors are a common practice in the pharmaceutical industry to incentivize long-term performance and align executive interests with shareholder value. This type of filing is standard for reporting such transactions.

Related Party Transactions

• The grant of restricted stock units to Director Nancy Lurker is a form of compensation and constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns director incentives with long-term shareholder value, but the immediate impact is dilution if shares are issued upon vesting.
• Employees: This filing does not directly impact employees, but it reflects standard compensation practices for board members.
• Management: The RSU grant is part of the overall compensation structure for key executives and directors.

Next Steps

• Director Nancy Lurker is expected to continue her service to meet the vesting conditions of the RSUs.
• The RSUs will vest on or before May 14, 2027, subject to continued service.
• Settlement of the RSUs will occur upon vesting or under specific trigger events as outlined in the grant agreement.

Key Dates

Keywords

Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU Grant, Collegium Pharmaceutical, Nancy Lurker, Director Compensation, Beneficial Ownership, Stock Vesting